10 citations as recorded by crossref.

1. Flucloxacillin bone and soft tissue concentrations assessed by microdialysis in pigs after intravenous and oral administration M. Bendtsen et al. 10.1302/2046-3758.101.BJR-2020-0250.R1
2. Initial antibiotic therapy for postoperative moderate or severe diabetic foot infections: Broad versus narrow spectrum, empirical versus targeted A. Nieuwland et al. 10.1111/dom.15228
3. Oral Flucloxacillin for Staphylococcal Osteomyelitis: Obsolete or Underused? S. Tevell & B. Christensson 10.7150/jbji.42852
4. Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid P. Drennan et al. 10.1111/bcp.14887
5. Assessment and management of diabetes‐related foot infection according to the new International Working Group on the Diabetic Foot guidelines 2023—Multidisciplinary grand rounds K. Hon et al. 10.1002/dmrr.3737
6. Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue– Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations K. Öbrink-Hansen et al. 10.1007/s11095-022-03197-y
7. Negligible Substituent Effect as Key to Synthetic Versatility: a Computational‐Experimental Study of Vinyl Ethers Addition to Nitrile Oxides A. Kutskaya et al. 10.1002/slct.202200174
8. Steady-state concentrations of flucloxacillin in porcine vertebral cancellous bone and intervertebral disc following oral and intravenous administration assessed by microdialysis M. Bendtsen et al. 10.1007/s00586-022-07208-9
9. Not recommended fixed-dose antibiotic combinations in low- and middle-income countries – the example of Tanzania K. Vliegenthart-Jongbloed & J. Jacobs 10.1186/s13756-023-01238-8
10. Three Weeks Versus Six Weeks of Antibiotic Therapy for Diabetic Foot Osteomyelitis: A Prospective, Randomized, Noninferiority Pilot Trial K. Gariani et al. 10.1093/cid/ciaa1758